Global Biosimilar Growth Hormones Market Report 2020-2030: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome & Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
Major players in the biosimilar growth hormone market are Biopartners And LG Chem, Amega Biotech, Eli Lilly and Company, Genetech Inc., Novartis AG, Zhongshan Hygene Biopharm Co. Ltd., Merck, Sanofi S.A., Biosidus and Ferring Pharmaceuticals.
The global biosimilar growth hormones market is expected to decline from $0.55 billion in 2019 to $0.53 billion in 2020 at a compound annual growth rate (CAGR) of -2.92%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $0.69 billion in 2023 at a CAGR of 9.07%.
The biosimilar growth hormone market consists of sales of Somatropin or human growth hormone (HGH) and related services by entities (organizations, sole traders and partnerships) that manufacture growth hormones. Biosimilar growth hormones are used to stimulate growth, cell reproduction and cell regeneration in humans and other animals.
North America was the largest region in the biosimilar growth hormones market in 2019. Asia Pacific was the second-largest region in the market.
The biosimilar growth hormone market covered in this report is segmented by route of administration into intravenous; subcutaneous; intramuscular; oral. It is also segmented by application into growth hormone deficiency; turner syndrome; idiopathic short stature; prader willi syndrome; others and by distribution channel into hospital and retail pharmacy; online pharmacy/epharmacy; specialty clinics.
In October 2018, Strongbridge Biopharma Plc entered into an agreement with Novo Nordisk to acquire the U.S. and Canadian rights of MACRILENT (macimorelin) for a deal amount of $145 million. The deal is expected to boost Novo Nordisk's biopharma business. Macrilen is an oral growth hormone secretagogue receptor agonist that is indicated for the diagnosis of adult growth hormone deficiency (AGHD). Strongbridge Biopharma is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with unmet needs.
The growing awareness about the side effects caused by the continuous usage of the biosimilar growth hormones is expected to restrict the growth of the market. Possible side effects of HGH use include nerve, muscle, or joint pain, swelling due to fluid in the body's tissues (edema), carpal tunnel syndrome, numbness and tingling of the skin, and high cholesterol levels. Continuous dosage of HGH can also increase the risk of diabetes and contribute to the growth of cancerous tumors, thus restraining the growth of the market.
Recombinant DNA technology (rDNA technology) is increasingly being implemented in the biosimilar growth hormone industry. The development of biosimilar growth hormone by using recombinant DNA technology (rDNA technology) is an emerging trend. For instance, in 2018, Genevatropin was produced utilizing Recombinant DNA Secretion Technology. Genevatropin (Genevatropin [rDNA origin] injectable delivery) is a pharmaceutical solution that supplements the natural human growth hormone for people who may be deficient in this hormone.
The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market. Growth hormone deficiency is caused by damage to the pituitary gland or hypothalamus, which may be the result of an abnormal formation that occurred before the child was born (congenital) or something that occurred during or after birth (acquired). Growth hormone deficiency has been identified in about 1 in every 3,800 babies.
Additionally, some children acquire it later in their life as a result of a brain tumor, brain operation, radiation therapy, injury or infection. Thus, an increase in the number of children suffering from growth deficiency drives the growth of the market.
Key Topics Covered:
1. Executive Summary
2. Biosimilar Growth Hormones Market Characteristics
3. Biosimilar Growth Hormones Market Size And Growth
3.1. Global Biosimilar Growth Hormones Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Biosimilar Growth Hormones Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Biosimilar Growth Hormones Market Segmentation
4.1. Global Biosimilar Growth Hormones Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Biosimilar Growth Hormones Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Growth Hormone Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader Willi Syndrome
4.3. Global Biosimilar Growth Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Hospital And Retail Pharmacy
- Online Pharmacy/ePharmacy
- Speciality Clinics
5. Biosimilar Growth Hormones Market Regional And Country Analysis
5.1. Global Biosimilar Growth Hormones Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Biosimilar Growth Hormones Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Biopartners And LG Chem
- Amega Biotech
- Eli Lilly and Company
- Genetech Inc.
- Novartis AG
- Zhongshan Hygene Biopharm Co. Ltd.
- Sanofi S.A.
- Ferring Pharmaceuticals
- Novo Nordisk A/S
For more information about this report visit https://www.researchandmarkets.com/r/cqqcdc
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900